Based on DESTINY-Breast04 results which showed
Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by
The approval by the
.
(C) 2022 M2 COMMUNICATIONS, source
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,409 GBX | +0.40% | +2.01% | +17.08% |
06:21am | HBM Holdings Unit, AstraZeneca Sign License, Option Agreement for Targeted Cancer Treatment; Shares Rise 16% | MT |
05-22 | Behind the numbers: AstraZeneca aims for sales of $80 billion by 2030 |
Based on DESTINY-Breast04 results which showed
Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by
The approval by the
.
(C) 2022 M2 COMMUNICATIONS, source
1st Jan change | Capi. | |
---|---|---|
+17.08% | 244B | |
+37.74% | 723B | |
+34.34% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+9.70% | 208B | |
-4.62% | 205B | |
+2.81% | 168B | |
+7.43% | 166B |